Literature DB >> 16790793

CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Paula M Chilton1, Thomas C Mitchell.   

Abstract

Adjuvant-induced survival of T cells after antigen activation correlates with increased expression of Bcl-3. Bcl-3 is an NF-kappaB/IkappaB family member and has been implicated in transcriptional regulation in several cell types. We tested the ability of mice deficient in Bcl-3 (Bcl-3 KO) to exhibit T-cell adjuvant-induced survival after challenge with the superantigen staphylococcal enterotoxin B (SEB), using lipopolysaccharide (LPS) as a natural adjuvant. These studies showed that Bcl-3 is required for secondary gamma interferon (IFN-gamma) production by CD8 T cells but not for adjuvant-induced survival effects. Specifically, wild-type and Bcl-3 KO mice exhibited comparable long-term increases in the Vbeta8(+) T-cell populations, indicating no lack of survival in response to adjuvant stimulation in the Bcl-3 KO activated T cells. Ectopic expression of the Bcl-3-related molecules IkappaBalpha, IkappaBbeta, and IkappaBepsilon in SEB-activated T cells increased survival during in vitro culture in the absence of adjuvant, suggesting that these IkappaB molecules could exert a survival function in antigen-activated T cells in place of Bcl-3. However, Vbeta8(+) CD8 T cells from SEB- plus LPS-treated Bcl-3 KO mice produced less IFN-gamma upon in vitro restimulation than Vbeta8(+) CD8 T cells from wild-type mice. Therefore, Bcl-3 plays a unique role in the regulation of IFN-gamma production in this model system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790793      PMCID: PMC1489710          DOI: 10.1128/IAI.01749-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Measurement of daughter cell accumulation during lymphocyte proliferation in vivo.

Authors:  Bruce S Thompson; Thomas C Mitchell
Journal:  J Immunol Methods       Date:  2004-10-27       Impact factor: 2.303

2.  The IkappaB protein Bcl-3 negatively regulates transcription of the IL-10 gene in macrophages.

Authors:  Marc Riemann; Robert Endres; Susanne Liptay; Klaus Pfeffer; Roland M Schmid
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

3.  Opposing roles for RelB and Bcl-3 in regulation of T-box expressed in T cells, GATA-3, and Th effector differentiation.

Authors:  Radiah A Corn; Chris Hunter; Hsiou-Chi Liou; Ulrich Siebenlist; Mark R Boothby
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

4.  Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter.

Authors:  Mohammad Jamaluddin; Sanjeev Choudhary; Shaofei Wang; Antonella Casola; Ruksana Huda; Roberto P Garofalo; Sutapa Ray; Allan R Brasier
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.

Authors:  Mohamed L Salem; Andre N Kadima; David J Cole; William E Gillanders
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

6.  Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells.

Authors:  Javier O Valenzuela; Christopher D Hammerbeck; Matthew F Mescher
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

7.  Initial T cell frequency dictates memory CD8+ T cell lineage commitment.

Authors:  Amanda L Marzo; Kimberly D Klonowski; Agnes Le Bon; Persephone Borrow; David F Tough; Leo Lefrançois
Journal:  Nat Immunol       Date:  2005-07-17       Impact factor: 25.606

8.  Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice.

Authors:  S T Ong; M L Hackbarth; L C Degenstein; D A Baunoch; J Anastasi; T W McKeithan
Journal:  Oncogene       Date:  1998-05-07       Impact factor: 9.867

9.  BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages.

Authors:  Jennifer Wessells; Mark Baer; Howard A Young; Estefania Claudio; Keith Brown; Ulrich Siebenlist; Peter F Johnson
Journal:  J Biol Chem       Date:  2004-10-01       Impact factor: 5.157

10.  A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism.

Authors:  A Khoruts; A Mondino; K A Pape; S L Reiner; M K Jenkins
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

View more
  6 in total

1.  The tumor promoter and NF-κB modulator Bcl-3 regulates splenic B cell development.

Authors:  Xiaoren Zhang; Andrea Paun; Estefania Claudio; Hongshan Wang; Ulrich Siebenlist
Journal:  J Immunol       Date:  2013-11-15       Impact factor: 5.422

2.  Atypical IκB proteins - nuclear modulators of NF-κB signaling.

Authors:  Marc Schuster; Michaela Annemann; Carlos Plaza-Sirvent; Ingo Schmitz
Journal:  Cell Commun Signal       Date:  2013-04-11       Impact factor: 5.712

3.  Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation.

Authors:  Lin-Fu Zhou; Yi Zhu; Xue-Fan Cui; Wei-Ping Xie; Ai-Hua Hu; Kai-Sheng Yin
Journal:  Respir Res       Date:  2006-12-20

4.  The NF-κB regulator Bcl-3 restricts terminal differentiation and promotes memory cell formation of CD8+ T cells during viral infection.

Authors:  Hemant Jaiswal; Thomas Ciucci; Hongshan Wang; Wanhu Tang; Estefania Claudio; Philip M Murphy; Rémy Bosselut; Ulrich Siebenlist
Journal:  PLoS Pathog       Date:  2021-01-28       Impact factor: 6.823

Review 5.  Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation.

Authors:  Hui Liu; Lin Zeng; Yang Yang; Chunlei Guo; Hui Wang
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

6.  Transgenic Bcl-3 slows T cell proliferation.

Authors:  Michael F J Bassetti; Janice White; John W Kappler; Philippa Marrack
Journal:  Int Immunol       Date:  2009-02-10       Impact factor: 4.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.